Skip to main content
. 2012 May;166(1):210–220. doi: 10.1111/j.1476-5381.2011.01662.x

Figure 4.

Figure 4

(A) Peak HR depressor response in bpm and (B) peak MAP depressor response in mmHg produced by i.c.v. guanabenz (50 µg in 5 µL) in conscious male Sprague-Dawley rats pre-treated i.c.v. with either saline (24 h; 5 µL), yohimbine (10 min; 5.9 µg; 15 nmol) or a SCR, Gαi1, Gαi2, Gαi3, Gαo or Gαs ODN (24 h; 25 µg in 5 µL each) (n= 6 per group). The values are the mean ± SEM. *P < 0.05, compared with i.c.v. SCR ODN-pre-treated animal group value. **P < 0.01, compared with i.c.v. SCR ODN-pre-treated animal group value; one-way anova. Note that these data were obtained in the same animals for which protein expression data is presented in Figure 2.